Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 5/20 | 0.60 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926045 | 0.86 | IMPDH2 (0.56) | IMPDH2IMPDH1MAP4K4NOTUMCYP3A4 | |
| SCHEMBL8347880 | 0.81 | IMPDH2 (0.62) | IMPDH2IMPDH1MAP4K4NOTUMTSHR | |
| SCHEMBL6168364 | 0.79 | IMPDH2 (0.65) | IMPDH2IMPDH1MAP4K4NOTUMPTK2 | |
| SCHEMBL21031069 | 0.79 | IMPDH2 (0.59) | IMPDH2IMPDH1NOTUMTSHRPTK2 | |
| SCHEMBL5779035 | 0.79 | IMPDH2 (0.60) | IMPDH2IMPDH1MAP4K4NOTUMPTK2 | |
| SCHEMBL19823860 | 0.79 | IMPDH2 (0.47) | IMPDH2IMPDH1MAP4K4NOTUMPTK2 | |
| SCHEMBL29454983 | 0.79 | IMPDH2 (0.60) | IMPDH2IMPDH1MAP4K4NOTUMPTK2 | |
| SCHEMBL6169923 | 0.79 | IMPDH2 (0.60) | IMPDH2IMPDH1MAP4K4NOTUMPTK2 | |
| SCHEMBL5780722 | 0.79 | IMPDH2 (0.60) | IMPDH2IMPDH1MAP4K4NOTUMPTK2 | |
| SCHEMBL16414084 | 0.79 | CSNK2A1 (0.49) | IMPDH2IMPDH1MAP4K4NOTUMPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630542-B2 | Compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium | ENDOGENA THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12195452-B2 | N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases | ENDOGENA THERAPEUTICS, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| CN-113227086-B | N- (4- (oxazol-5-yl) phenyl) chroman-3-carboxamide derivatives and related compounds as stimulators of production of retinal precursor cells for the treatment of neuroretinal disorders | 内生疗法公司 | 2024-07-26 | — | — | CN | disclosed |
| EP-3902798-B1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS INC (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-3902798-B1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230322749-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ENDOGENA THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322749-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ENDOGENA THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322749-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ENDOGENA THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4167999-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | Endogena Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115916192-A | Novel compounds and their use as therapeutically active substances for the treatment and/or prophylaxis of diseases in which the retinal pigment epithelium is involved | 内生疗法公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20200207719-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT OF RETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| WO-2020140043-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2014079850-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014079850-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-30 | — | — | WO | disclosed |
| US-7329681-B2 | Inhibitors of IMPDH enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329681-B2 | Inhibitors of IMPDH enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1126843-A4 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6399773-B1 | AUTOIMMUNE DISEASE; TRANSPLANTING ORGANS | BRISTOL-MYERS SQUIBB CO. | 2002-06-04 | — | — | US | disclosed |
| EP-1126843-A1 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025780-A1 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207719-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT OF RETINAL DISEASES | ALDH1A2, NR2E3, PDE6D | IMPDH2 4173/4885IMPDH1 4240/4885MAP4K4 3485/4885 |
| US-20230322749-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ALDH1A2, NR2E3, RB1 | IMPDH2 4176/4885IMPDH1 4302/4885MAP4K4 3091/4885 |
| US-12630542-B2 | Compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium | ALDH1A2, NR2E3, GFRA1 | IMPDH2 3741/4885IMPDH1 3736/4885MAP4K4 3739/4885 |
| US-12195452-B2 | N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases | NR2E3, GFRA2, ALDH1A2 | IMPDH2 3270/4885IMPDH1 3631/4885MAP4K4 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.